相关临床试验
21
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1890
已完成
16
76.2%
终止
2
9.5%
Unknown
3
14.3%
暂无批准数据
- NDSU and Sanford Health are launching a study to assess real-world impacts of GLP-1 medications on quality of life, emotional state, and muscle wasting. - The study will follow participants at treatment start, three months, and six months, with enrollment expected to open in late July. - Researchers note early literature hints GLP-1s may be protective against substance use issues, unlike bariatric surgery where 1 in 5 patients develop such problems. - An estimated 1 in 8 Americans now take a GLP-1 drug, yet long-term outcomes and complications remain poorly understood.
- Research reveals that approximately 25% of e-scooter injuries involve riders who were under the influence of alcohol or drugs, with hospital data showing an eightfold increase in scooter-related hospitalizations between 2016 and 2021. - Intoxicated e-scooter riders face nearly double the risk of concussion or brain injury compared to sober riders, with treatment costs averaging $4,600 higher per patient according to a study published in The American Surgeon. - E-scooter injuries have tripled from 23,000 in 2019 to nearly 66,000 by 2022, with young males aged 18-39 representing the highest risk group, prompting calls for stronger safety regulations and enforcement.
